Abstract
Pregnancy registries are the most commonly used data resource for the post-marketing surveillance of drug teratogenicity. However, the limited sample size and potential selection bias in these registries has led us to investigate the potential of the UK General Practice Research Database (GPRD) as an alternative data source for monitoring drug safety during pregnancy. In addition, a literature review identified further observational data sources that monitor pregnancy outcomes for future evaluation.
Initial feasibility studies focused on the ability of the GPRD to capture pregnancy outcomes for a range of drug class exposures, all of which are currently under investigation in pregnancy registries, during pregnancy. The comparator pregnancy registries were identified via a MEDLINE search, whilst eligible pregnancies, in which women received one or more prescriptions for the drug of interest during pregnancy, were identified in the GPRD using the mother-baby link. The number of pregnancy outcomes following exposure to medication for arange of conditions with varying prevalence, including depression, migraine, epilepsy, herpes simplex and HIV, captured by the two data sources were compared. For depression, a relatively prevalent condition, the GPRD recorded the same number of mean annual intrauterine exposures to fluoxetine as the pregnancy registry (118 exposures/year). Ascertainment of intrauterine exposure to drug treatments for less prevalent conditions was found to be higher for the pregnancy registries than the GPRD; for the older antiepileptic drugs (valproate and carbamazepine), the pregnancy registry recorded between four and five times as many mean annual exposures as the GPRD. Virtually no antiretroviral exposures (three) were identified during the time period of interest on the GPRD, compared with 3946 in the Antiretroviral Pregnancy Registry.
Data from the GPRD meet established criteria for evaluating outcomes of pregnancy. For prevalent conditions, it has the potential to replace or work alongside standard pregnancy registries and the alternative data sources identified. Further studies are now needed to assess its ability to replicate known teratogenic associations.
Similar content being viewed by others
References
Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60(6): 356–64
Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30(1): 24–9
Koren G, Pastuszak A, Ito S, et al. Drugs in pregnancy. N Engl J Med 1998; 338(16): 1128–37
Hoar R. Developmental toxicity: extrapolation across species. J Am Coll Toxicol 1995; 14: 11–20
Hardy JR, Holford TR, Hall GC, et al. Strategies for identifying pregnancies in the automated medical records of the General Practice Research Database. Pharmacoepidemiol Drug Saf 2004; 13(11): 749–59
Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77(2): 193–8
Kendle International Inc. Lamotrigine pregnancy registry [online]. Available from URL: http://www.kendle.com/registries [Accessed 2007 Nov 22]
Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for January 1989 through 31 July 2005 [online]. Available from URL: http://www.kendle.com/registries [Accessed 2007 Nov 22]
Kendle International Inc. Sumatriptan and Naratriptan Pregnancy Registry International Interim Report. 1 January 1996 through 31 October 2005 [online]. Available from URL: http://www.kendle.com/registries [Accessed 2007 Nov 22]
Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89(5): 713–8
Glaxo Welcome. Acyclovir Pregnancy Registry and Valacyclovir Pregnancy Registry. Final Study Report. 1 June 1984–30 April 1999 [online]. Available from URL: http://pregnancyregistry.gsk.com/acyclovir.html [Accessed 2007 Nov 22]
Leen-Mitchell M, Martinez L, Gallegos S, et al. Mini-review: history of organized teratology information services in North America. Teratology 2000; 61(4): 314–7 51
Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996; 69(2): 83–9
Centre for Epidemiology. The Swedish Medical Birth Register: a summary of content and quality, 2003 [online]. Available from URL: http://www.sos.se/fulltext/112/2003-112-3/2003-112-3.pdf [Accessed 2006 Jun 30]
Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand 2000; 79(6): 435–9
Hemminki E, Teperi J, Tuominen K, et al. Need for and influence of feedback from the Finnish birth register to data providers. Qual Assur Health Care 1992; 4(2): 133–9
Christensen K, Knudsen LB. Registration of congenital malformations in Denmark. Dan Med Bull 1998; 45(1): 91–4
Government of Saskatchewan. Saskatchewan Health. Saskatchewan’s health services information resources, July 2002 [online]. Available from URL: http://www.health.gov.sk.ca/programs-services [Accessed 2007 Nov 22]
Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 2005; 90(5): F355–8
Garcia Rodriguez L, Perez-Gutthann S, Jick S. The UK General Research Practice Database. In: Strom B, editor. Pharmacoepidemiology. Chichester: John Wiley, 2000: 375–85
Li DK, Liu L, Odouli R, et al. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327(7411): 368
Hartert TV, Neuzil KM, Shintani AK, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol 2003; 189(6): 1705–12
Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16(5): 474–84
Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep 2001; 116 Suppl. 1: 32–40
Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343(22): 1608–14
Czeizel AE, Petik D, Vargha P. Validation studies of drug exposures in pregnant women. Pharmacoepidemiol Drug Saf 2003; 12(5): 409–16
Castilla EE, Orioli IM, Orioli IM. ECLAMC: the Latin-American collaborative study of congenital malformations. Community Genet 2004; 7(2–3): 76–94
Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in The Netherlands. BJOG 2006; 113(5): 559–68
Olsen J, Czeizel A, Toft Sørensen H, et al. How do we best detect toxic effects of drugs taken during pregnancy? Drug Saf 2002; 25(1): 21–32
US Department of Health and Human Sciences Food and Drug Administration, Center for Drug Evaluation and Research, and Centre for biologics Evaluation and Research. Reviewer guidance. Evaluation of human pregnancy outcome data, 1999 [online]. Available from URL: http://www.fda.gov/cder/guidance/6777fnl.htm#_TOC79910680 [2006 Sep 30]
Velentgas P, Cole JA, Mo J, et al. Severe vascular events in migraine patients. Headache 2004; 44(7): 642–51
Olsen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12: 497–501
Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003; 349(26): 2556–9
Covington DL, Tilson H, Elder J, et al. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the antiretroviral pregnancy registry. Pharmacoepidemiol Drug Saf 2004; 13(8): 537–45
Acknowledgements
The authors thank Dr Janet Cragan for her contribution and comments to the earlier drafts of this paper and also Deepak Sriramulu for his assistance with the analyses.
No sources of funding were used in the preparation of this review article. Miss Charlton and Drs Cunnington and Weil are employees of and hold shares in GlaxoSmithKline. Dr de Vries has no conflicts of interest that are directly relevant to the content of this review article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Charlton, R.A., Cunnington, M.C., de Vries, C.S. et al. Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes. Drug-Safety 31, 39–51 (2008). https://doi.org/10.2165/00002018-200831010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200831010-00004